期刊文献+

胸腺肽α1对乳腺癌患者外周血细胞免疫功能的影响 被引量:5

下载PDF
导出
摘要 目的探讨胸腺肽α1对乳腺癌患者外周血细胞免疫功能的影响。方法应用流式细胞术对86例来自不同分期的乳腺癌患者外周血T淋巴细胞及自然杀伤细胞(NK细胞)活性进行检测,比较其与乳腺良性病变患者的差别。将86例乳腺癌患者随机分为两组,一组接受胸腺肽α1治疗(注射组);另一组未接受胸腺肽α1治疗(未注射组)。结果乳腺癌患者CD4、CD8、NK细胞百分比,以及CD4/CD8比值均低于乳腺良性瘤患者(P<0.01);注射组上述各项指标均高于未注射组(P<0.05)。结论使用胸腺肽α1可在一定程度上提高患者外周血细胞免疫功能。
出处 《重庆医学》 CAS CSCD 北大核心 2011年第32期3307-3309,共3页 Chongqing medicine
  • 相关文献

参考文献8

  • 1Kuss I, Hathaway B, Ferris RL, et al. Decreased absolute counts of T lymphocyte subsets and tileir relation to dis- ease in squamous cell carcinoma of the head and neck[J]. Clin Cancer Res, 2004,10 (11) : 3755-3762.
  • 2Kennedy K,Celis E. Multiple roles for CCD4 + T cells in anti-tumor immune responses[J]. Immunol Rev, 2008,222 (1) :29-44.
  • 3Van der Vliet HJ,Koon HB,Atkins MB, et al. Exploiting regulatory T-cell populations for the immunotherapy of cancer[J]. Immunother, 2007,30(6) : 591 595.
  • 4Hanna J, Mandelboim O. When killers became helpers [J]. Trends Immunol, 2007,28 (5) : 201-206.
  • 5Low TL, Goldstein AL. Thymosins.. structure, functionand the therapeutic applications [ J ]. Thymus, 1984,6 ( 1 / 2) :27-42.
  • 6董兰凤,吕占军,刘京生.肿瘤的靶向治疗不同途径的研究进展[J].细胞与分子免疫学杂志,2003,19(6):623-625. 被引量:10
  • 7Giuliani C, Napolitano G, Mastino A, et al. Thymosin-al- pha regulates MHC class I expression in FRTL-5 cells at Transcriptional level[J]. Eur J Immunol, 2000, 30 (3): 778-786.
  • 8Rasi G,Terzoli E,Izzo F, et al. Combined treatment with thymosin-alphal and low dose interferon-alpha after da- carbazine in advanced melanoma[J]. Melanoma Res,2000, 10(2) : 189-192.

二级参考文献20

  • 1[1]Mark P, Dennis S. Biological rationale for HER2/neu as a target for monoclonal antibody therapy[J]. Seminars in Oncology, 2000, 27(5, Suppl 9): 13-19.
  • 2[2]Ravdin PM, Chamness GC. The cerbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular marker-a review[J]. Gene, 1995, 159:19.
  • 3[3]Fornier M, Esteva FJ, Seidman AD, et al. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer[J]. Semin Oncol, 2000, 27(6 Suppl 11): 38- 45.
  • 4[4]Christiane JB, Wenbiao L, Darren WD, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases[J]. Cancer, 2000, 89: 488- 499.
  • 5[5]Paul P, Takashi M, Keiji I, et al. Anti-epidermal growth gactor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice[J]. Clinical Cancer Research, 1999, 5: 257-264.
  • 6[6]Carol M R, Sally J, DeNardo. Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies[J]. Critical Reviews in Oncology/Hematology, 2001, 38: 25-35.
  • 7[7]Bagshawe KD. Antibody directed enzymes revive anti-cancer prodrug concept[J]. Br J Cancer, 1987, 56: 531-532.
  • 8[8]Konstantions NS, Agamemnon AE. Antibody directed prodrug therapy(ADEPT): A review of the experimental and clinical consideration[J]. Cancer Res, 1999, 19: 605-614.
  • 9[9]Huwyler J, Yang J, Pardridge WM, et al. Receptor mediated delivery odaunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat[J]. J Pharmacol Exp Ther, 1997, 282: 1541-1546.
  • 10[10]Woodle MC, Lasic DD. Sterically stabilized liposomes[J]. Biochim Biophys Acta, 1992, 1113(2): 171-199.

共引文献9

同被引文献68

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部